Our mission Kejako, in the field of ophthalmology, merge Medtech and Engineering expertise to develop solution for interested presbyopic patients seeking to keep quality of life through the compensation of visual accommodation decay. We address presbyopia with an anti-aging mindset to treat the gradual loss of visual accommodation. Our promise, unlike any other existing surgical solution, is to provide non-invasive (ultra-minimally invasive or a “no-cut”) laser solution to delay the need for reading glasses without compromising the patient’s quality of vision. Our solution will be fully personalized to the patient by using our simulation expertise which is already recognized by our peers as we provide simulation services to strategic partners. We have the potential to become the next generation standard of care in personalized ophthalmic anti-aging medicine. Our company Kejako is privately held company based in Switzerland and financed since March 2015 Patents pending: 4 EP since March 2017 and 3 PCT since March 2018 Preparing 6 MCHF B Series + 15MCHF C Series for pre-clinical and clinical validation of Phakorestoration before go to market.